Cantor Fitzgerald set a $140.00 target price on AnaptysBio (NASDAQ:ANAB) in a research note released on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently weighed in on ANAB. Credit Suisse Group set a $147.00 price target on shares of AnaptysBio and gave the stock a buy rating in a research report on Thursday, September 27th. Wedbush reaffirmed an outperform rating and set a $138.00 price target on shares of AnaptysBio in a research report on Tuesday, September 18th. Zacks Investment Research cut shares of AnaptysBio from a buy rating to a hold rating in a research report on Tuesday, October 9th. Stifel Nicolaus set a $127.00 price target on shares of AnaptysBio and gave the stock a buy rating in a research report on Friday, September 14th. Finally, JMP Securities decreased their price target on shares of AnaptysBio from $180.00 to $153.00 and set a buy rating for the company in a research report on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $130.50.

AnaptysBio stock traded down $8.71 during trading on Friday, reaching $72.33. 836,519 shares of the company’s stock were exchanged, compared to its average volume of 312,129. The company has a current ratio of 16.19, a quick ratio of 16.19 and a debt-to-equity ratio of 0.01. AnaptysBio has a 52-week low of $65.93 and a 52-week high of $134.00. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -47.59 and a beta of 3.47.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.05. The business had revenue of $5.00 million for the quarter. Analysts forecast that AnaptysBio will post -2.72 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Partner Investment Management L.P. boosted its position in AnaptysBio by 82.8% in the 2nd quarter. Partner Investment Management L.P. now owns 1,709 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 774 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in AnaptysBio in the 3rd quarter valued at about $203,000. Great West Life Assurance Co. Can boosted its position in AnaptysBio by 65.9% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,057 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 817 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in AnaptysBio in the 2nd quarter valued at about $211,000. Finally, United Services Automobile Association boosted its position in AnaptysBio by 27.9% in the 2nd quarter. United Services Automobile Association now owns 3,138 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 685 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Recommended Story: Book Value Per Share in Stock Trading

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.